{
    "symbol": "AVXL",
    "quarter": 1,
    "year": 2022,
    "date": "2022-02-09 18:25:24",
    "content": "  The first quarter marked significant progress across our portfolio, highlighted by the positive top line results of the randomized placebo-controlled AVATAR Phase 3 study for the treatment of adult patients with Rett syndrome and the positive top line results from the placebo-controlled Phase 1 study of ANAVEX 3-71, which is in development for the treatment of neurodegenerative diseases, including FTD, Frontotemporal Dementia and a clinical data-driven evidence of efficacy and safety of our broad SIGMAR1 platform portfolio, which allows us to plan and to expand further into the rare disease space, including implementing expanded access for adult patients with Rett syndrome, an underserved population."
}